Development of radiation-sensitizing anti-cancer agents using G2 checkpoint aberogator
| Project/Area Number |
22700913
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Clinical oncology
|
|---|
| Research Institution | Akita University |
|---|
Principal Investigator |
KOIZUMI Yukio 秋田大学, 大学院・医学系研究科, 助教 (80353465)
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2010: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | 抗がん物質探索 / ケミカルバイオロジー / 放射線 / 細胞周期 / シグナル伝達 / 癌 |
|---|
| Research Abstract |
The present study aims at examing the radiation-sensitizing effect of G2 checkpoint abrogators against solid cancers and discovering the new anti-cancer agent which brings both benefits, enhancing the therapeutic efficacy and decreasing adverse effects of cancer radiotherapy. We examined the effects of various G2 checkpoint abrogators on G2 arrest induction and antiproliferative effect by X-ray irradiation against esophageal cancer cell line, TE5. Cell cycle analysis and trypan blue exclusion assay showed that UCN-01 abrogated G2 arrest and potentiated growth inhibition, respectively. Furthermore, Western blotting demonstrated that UCN-01 decreased the protein level of Chk1 kinase activated by X-ray irradiation.
|
Report
(3 results)
Research Products
(17 results)
